Eugene Chung, MD
Radiation Oncology · Denver, CONPI 1285834945
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $958 of the $1,482 with a category attached, or 64.7%. 7 manufacturers reported payments, led by Tersera Therapeutics LLC at 33.7% of the total.
Across 13 payments — averaging $114.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tersera Therapeutics LLC$500
- Novocure Inc.$265
- Medtronic$263
- Monteris Medical Corporation$223
- Tactile Systems Technology Inc$169
- Myovant Sciences Inc.$43
- plus $19 from 1 others
What the payments were for
- Consulting fees$50034%
- Food & beverage$95865%
- Education$242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tersera Therapeutics LLC | 1 | $500 |
| Novocure Inc. | 3 | $265 |
| Medtronic | 3 | $263 |
| Monteris Medical Corporation | 1 | $223 |
| Tactile Systems Technology Inc | 2 | $169 |
| Myovant Sciences Inc. | 2 | $43 |
| AstraZeneca | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOLADEX$500
- Neuroblate$223
- Optune$195
- Flexitouch Plus$154
- Entre Plus$154
- OSTEOCOOL RF ABLATION SYSTEM$151
How this compares
$1,482 in reported general payments places this provider in the 75th percentile of 105 radiation oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 29 | $503 |
| Lidocaine Hcl ViscousLidocaine Hcl | 16 | $258 |
| Oxycodone Hcl | 12 | $93 |
| Omeprazole | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Denver
- Thomas PughDenver$15K
- Seth ReinerDenver$2K
- Christopher DeigDenver$2K
- Mark ChidelDenver$1K
- Ari BallonoffDenver$375
- Andrzej WojcieszynskiDenver$369
- Peter RossiGlenwood Springs$146K
- Suraj SinghGreely$134K
- Meera PatelAurora$112K
- David RabenAurora$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.